Physician profile
Lauren Thompson
NPI 1295267797
$14,838.71
in general payments reported to CMS, 2019-2025
17 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Medical Biochemical Genetics providers received nationally (typical 2025 total: $149).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2022: $288 · 2023: $543 · 2024: $93.26 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Travel and Lodging: $1,223 · Food and Beverage: $1,177 · Honoraria: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,725.00 |
| Travel and Lodging | $1,222.91 |
| Food and Beverage | $1,177.39 |
| Honoraria | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $7,648.44 | 2025 | Cholbam, Ctexli, Livmarli |
| Sarepta Therapeutics, INC. | $5,708.43 | 2023-2025 | Elevidys |
| Chiesi USA, INC. | $300.00 | 2025 | Elfabrio |
| Biomarin Pharmaceutical INC. | $240.42 | 2019-2023 | Voxzogo 1.2mg, Palynziq |
| Ns Pharma, INC. | $171.60 | 2023 | Viltepso |
| Horizon Therapeutics Plc | $119.81 | 2022 | |
| Cycle Pharmaceuticals INC | $113.76 | 2024-2025 | Javygtor |
| Ptc Therapeutics, INC. | $102.00 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $98.45 | 2023-2024 | Dojolvi |
| Takeda Pharmaceuticals U.S.A., INC. | $67.15 | 2022-2023 | Vpriv |
| Ipsen Biopharmaceuticals, INC | $54.30 | 2023 | Sohonos |
| Amicus Therapeutics, INC. | $52.63 | 2024-2025 | |
| Immedica Pharma US, INC. | $44.77 | 2022-2023 | |
| Ucb, INC. | $33.89 | 2023 | |
| Alexion Pharmaceuticals, INC. | $33.17 | 2025 | Strensiq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $25.99 | 2023 | Cholbam |
| Albireo Pharma, INC. | $23.90 | 2023 | Bylvay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.